- Open Access
Antiviral potency and functional analysis of tetherin orthologues encoded by horse and donkey
© Yin et al.; licensee BioMed Central Ltd. 2014
- Received: 3 June 2014
- Accepted: 22 August 2014
- Published: 27 August 2014
Tetherin is an interferon-inducible host cell factor that blocks the viral particle release of the enveloped viruses. Most knowledge regarding the interaction between tetherin and viruses has been obtained using the primate lentiviral system. However, much less is known about the functional roles of tetherin on other lentiviruses. Equine infectious anemia virus (EIAV) is an important macrophage-tropic lentivirus that has been widely used as a practical model for investigating the evolution of the host-virus relationship. The host range of EIAV is reported to include all members of the Equidae family. However, EIAV has different clinical responses in horse and donkey. It’s intriguing to investigate the similarities and differences between the tetherin orthologues encoded by horse and donkey.
We report here that there are two equine tetherin orthologues. Compared to horse tetherin, there are three valine amino acid deletions within the transmembrane domain and three distinct mutations within the ectodomain of donkey tetherin. However, the antiviral activity of donkey tetherin was not affected by amino acid deletion or substitution. In addition, both tetherin orthologues encoded by horse and donkey are similarly sensitive to EIAV Env protein, and equally activate NF-κB signaling.
Our data suggest that both tetherin orthologues encoded by horse and donkey showed similar antiviral activities and abilities to induce NF-κB signaling. In addition, the phenomenon about the differential responses of horses and donkeys to infection with EIAV was not related with the differences in the structure of the corresponding tetherin orthologues.
- Equine tetherin
- Antiviral activity
Tetherin, an IFN-inducible, glycosylated restriction factor and type II membrane protein, is responsible for inhibiting the release of human immunodeficiency virus (HIV) and other enveloped viruses from infected cells[1, 2]. This viral release restriction factor contains a cytoplasmic N-terminal region, a transmembrane region, a coiled-coil ectodomain and a C-terminal glycosylphosphatidylinositol (GPI) anchor. Among the known proteins, this double-anchored topology is relatively unique and important for its antiviral restriction activity. Tetherin incorporates one of its two membrane anchors into viral membranes, and thereby traps enveloped viral particles on the surface of infected cells, leading to their internalization and degradation. As another function, it was recently reported that human tetherin acts as an innate sensor to activate NF-κB and promote pro-inflammatory gene expression[4, 5].
In turn, enveloped viruses have evolved different mechanisms to antagonize this restriction by tetherin. Influenza virus disrupts the interferon pathway to reduce the production of tetherin, thereby antagonize the antiviral activity of tetherin. Moreover, several different virus-encoded proteins have been implicated to counteract tetherin: human immunodeficiency virus type 1 (HIV-1) Vpu, the envelope glycoproteins encoded by HIV-2, SIVtan, feline immunodeficiency virus (FIV), EIAV, Ebola virus (GP), herpes simplex virus 1 (HSV-1) glycoprotein M, simian immunodeficiency virus (SIV) Nef, and Kaposi’s sarcoma-associated herpes-virus (KSHV) K5[7–16]. Recently it was shown that herpes simplex virus type 1 (HSV-1) induces tetherin mRNA degradation via its virion host shutoff activity to counteract tetherin restriction.
Equine infectious anemia virus (EIAV), which belongs to the Retroviridae family, is a non-primate enveloped virus that has been reported to infect all members of the Equidae family[18, 19]. The clinical cases and virus evolution have been well documented in horses, ponies, donkey and mules. However, susceptible to infection, donkeys do not develop clinical response. In addition, lower amounts of plasma associated virus are detected in donkeys compared to horses infected with EIAV. Recently, we have cloned the tetherin homologue of horse, and reported that horse tetherin can restrict EIAV release from infected cells and that its antiviral activity is antagonized by EIAV Env. Thus, it is intriguing to investigate the similarities and differences between the tetherin orthologues encoded by horse and donkey.
In this study, we investigated the similarities and differences between both equine tetherin orthologues. Donkey tetherin has a shorter sequence compared to those of its homologues. The amino acid sequence of donkey tetherin differs from that of horse tetherin in the transmembrane domains and ectodomains. However, both of them displayed similar antiviral activity against EIAV and HIV-1. In addition, the distinct amino acids between two equine tetherin orthologues didn’t govern the sensitivity to antagonism by EIAV Env. Interestingly, both equine tetherin orthologues lacking the tyrosine motif within cytoplasmic tail could activate the NF-κB signaling.
The tetherin homolog encoded by donkey (Equus asinus) is different from that of horse (Equus caballus)
Analysis of the post-translational modification and subcellular localization of two equine tetherin orthologues
The plasma membrane localization of human tetherin and its colocalization with virus particles are vital to its restriction function, as it need tether newly formed virions to the cell membrane. Due to the truncated transmembrane domain in donkey tetherin, it is not clear whether the subcellular localization of donkey tetherin is different from that of horse tetherin. To this end, HEK293T and HeLa cells were transfected with human, horse and donkey tetherins respectively, and the subcellular localizations of these constructs were analyzed by confocal immunofluorescence. As shown in Figure 2C, three tetherin proteins were preferentially localized at the plasma membrane. Three valine deletions in the transmembrane domain of donkey tetherin had no effect on its subcellular localization. Our results suggested that the plasma membrane localization was an inherent characteristic of two equine tetherin orthologues. This phenomenon is consistent with the model suggesting that tetherin restricts virus release by directly retaining the viral particle at the plasma membrane.
EIAV viral particle release is blocked by the two equine tetherin orthologues
In addition to restrict the release of viral particles from the cell surface, human tetherin was also reported to impair the infectivity of these progeny virions. To further investigate whether both equine tehterin orthologues displayed distinct effects on the infectivity of cell-free virions. HEK293T cells were co-transfected with constructs to produce VSV-G pseudotyped EIAV virions along with increasing amounts of plasmid for the expression of equine or human tetherins. The amounts of progeny virions in the culture supernatants were determined by measuring viral reverse transcriptase activity; the levels of infectious EIAV particles in the supernatants were determined by infecting the HKE293T cells. As shown in Figure 3C, our study further demonstrated that both horse and donkey tetherins also could diminish the infectivity of the cell-free virus particles, which is consistent with the results reported by other group. It is noted that the infectivity of vrions produced in HEK293T cells expressing donkey tetherin slightly lower than that in HEK293T cells expressing horse tetherin, but no significant difference was determined. Therefore, it is speculated that in addition to reduce the production of cell-free viruses, both horse and donkey tetherins also impair the infectivity of EIAV particles.
Two equine tetherin orthologues are similarly sensitive to EIAV Env
Both donkey and horse tetherins activate NF-κB
In conclusion, we showed that the tetherin homolog encoded by donkey (Equus asinus) is different from that of horse (Equus caballus). However, both equine tetherin orthologues displayed apparent antiviral activity against EIAV and HIV-1. In addition, the sensitivity of both equine tetherin orthologues to EIAV Env-mediated antagonism is similar. Surprising, both equine tetherin orthologues without dual-tyrosine motif could potently activate the NF-κB signaling.
Donkeys and horses used in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of the Harbin Veterinary Research Institute (HVRI), Chinese Academy of Agricultural Sciences. There were no animals sacrificed specifically for this study. Donkey and horse monocyte-derived macrophages (MDMs) were isolated from 200 mL peripheral blood taken from the jugular vein by veterinarians.
Human embryonic kidney (HEK) 293 T cells and HeLa cells were maintained at 37°C in a 5% CO2 incubator in Dulbecco’s modified Eagle’s medium (HyClone, USA) supplemented with 10% fetal bovine serum and penicillin/streptomycin (100units/ml).
Donkey and horse macrophage cultures derived from peripheral blood mononuclear cells were prepared from EIAV sero-negative animals. The purified donkey and horse primary macrophage cells were maintained in RPMI 1640 supplemented with 10% heat-inactivated horse serum, 30% heat-inactivated fetal bovine serum and penicillin/streptomycin (100 units/ml) (Gibco, USA).
Human and horse tetherin constructs (pEF-huTHN and pEF-horTHN) were constructed in our laboratory as previously described. The pNL-r-HSAS plasmid was obtained from Drs. Beth Jamieson and Jerome Zack through the NIH AIDS Reagent Program. Plasmid pLG3-8 is a full-length molecular clone of EIAVFDDV12 and was constructed from the provirus DNA of EIAVFDDV12. pCMV-EIAV is a derivative of the pLG3-8 plasmid. The U3 region of the 5’ LTR was replaced with the cytomegalovirus early promoter amplified from pcDNA3.1 plasmid (Invitrogen) by digestion with the restriction enzymes Mlu I and Xba I. Using these constructs as templates, EIAV GagPol was amplified from proviral plasmids and inserted as Eco RI-Not I fragments into the VR-1012 vector (a kind gift from Dr. Xiaofang Yu). pNF-κB-Luc was purchased from Stratagene. Tetherin chimeric constructs were generated from pEF-huTHN and pEF-horTHN by using the overlapping PCR, and then confirmed by nucleotide sequencing.
Identification and Cloning tetherin homologue from donkey macrophages
The primers (forward primer 5’-ATGGGGGACCACAGGCTGCTGAGAT-3’, reverse primer 5’-TCAGGCCTGCAGATCCCAGAGGCCC-3’) were designed using horse tetherin sequence. The cDNA fragment of potential donkey tetherin was amplified by RT-PCR from total RNA extracted from donkey macrophage cells. The amplified fragments were purified and cloned into the pEF-Flag-HA. The resultant expression plasmid for donkey tetherin was named pEF-donTHN. To determine the initiation site of donkey tetherin, 5’-RACE was performed using a 5’-Full RACE Core Set (Takara) as described previously. The DNA fragments encoding the full-length horse MAVS were amplified by RT-PCR using the primers (forward primer 5’CCAAGAATTCTATGACGGTTGCCGAGGACAAGACTT3’, reverse primer 5’CCAATCTAGAtcaCTGGAGCAGGCGCCTACGGTACAGC3’) and subcloned into EF-Flag-HA, resulting in the Flag/HA-fusion expression constructs pEF-HorMAVS.
Measurement of tetherin mRNA expression by real-time PCR
Total RNA was extracted from donkey and horse macrophage cells (2 × 106). 100 ng of total RNA was subjected to reverse transcription, and then subjected to real-time PCR using a SYBR Green® Master Mix kit (Invitrogen) according to the manufacturer’s protocols. The procedure to measure of tetherin mRNA expression by Real-time RT-PCR was described previously.
Virion release assays and Western blotting
Virus-like particle (VLP) release assays were performed by transfecting HEK293T cells. Briefly, HEK293T cells were cultured in 6-well plates and cotransfected with 5 μg of pEIAV-GagPol, or pNL-r-HSAS, and different amounts (from 100 ng to 2000 ng) of horse, human or donkey tetherin expression vector or empty vector using standard calcium phosphate transfection. Forty-eight hours post-transfection, the cells were harvested, lysed in lysis buffer (Tris–HCl pH 7.5, 50 mM NaCl, 5 mM EDTA and 1% Triton X-100) and then centrifuged at 10,000 × g for 5 min to remove the cell nuclei. The virus-containing supernatants were harvested and clarified by low-speed centrifugation at 10,000 × g for 10 min at 4°C. The VLPs that were released into the culture medium were further purified by centrifugation (20,000 × g for 2 h at 4°C) and then resuspended in phosphate-buffered saline (PBS). The intracellular Gag and tetherin proteins and pelleted virion particles were analyzed by Western blotting. The human, horse, and donkey tetherin proteins tagged with HA were detected with a mouse monoclonal anti-HA antibody (Sigma). EIAV Gag and Env were detected using EIAV-positive serum. HIV-1 Gag was detected with an anti-P24 monoclonal antibody, and β-actin was detected with an anti-β-actin antibody (Sigma). Alexa Fluor 800-labeled goat anti-mouse IgG and goat anti-horse IgG (Odyssey) were used as secondary antibodies. The blots were imaged with Odyssey using the 800 nm channel to visualize IRDye 800CW. Each experiment was performed independently at least three times.
Measuring virus infectivity
293 T cells cultured in 6-well plates were transfected with 1.5 ug pGagPolUK3, 1.5 ug pONY8.1luc (a kind gift from Dr. Carsten Munk), 0.5 ug the vesicular stomatitis virus G protein (VSV-G) expression plasmid, and increasing amount of human, horse or donkey tetherins by a standard calcium phosphate transfection. Forty-eight hours post-transfection, virus-containing supernatants were harvested and clarified by low-speed centrifugation at 12000 × g for 10 min at 4°C and used to infect naive 293 T cells after quantifing the reverse transcriptase activity of virus by using a RT kit (Roche, Germany). After Forty-eight hours post-infection, the infected 293 T cells were lysed in lysis buffer containing 50 mM Tris–HCl (PH7.4), 150 mM NaCl, 3 mM EDTA, and1%Triton X-100, the cytosolic fraction was used to determine luciferase activity with a luciferase assay kit (Promega).
HEK293T cells cultured in 24-well plates were co-transfected with the indicated tetherin constructs (200 ng) and pNF-κB-Luc plasmid (50 ng) in combination with 10 ng/well pRL-TK (as an internal control to normalize the transfection efficiency, Promega). Luciferase assays were performed at 36 h after transfections. Firefly luciferase and Renilla luciferase activities were quantified using the Dual-Luciferase Assay Kit (Promega) as per manufacturer’s instructions. Statistical analysis was performed using PRISM (GraphPad).
We thank Dr. Bruce Chesebro and Kathy Wehrly for providing HIV-1 p24 Monoclonal Antibody (183-H12-5C) through NIH AIDS Reagent Program. This study was supported by grants from the national natural science foundation of China to X.W. (31072113 and 31222054), grant from the Central Public-interest Scientific Institution Basal Research Fund (2012ZL080) and grants from the State Key Laboratory of Veterinary Biotechnology (SKLVBP201205,SKLVBP201304).
- Neil SJ: The antiviral activities of tetherin. Curr Top Microbiol Immunol 2013, 371: 67-104.PubMedGoogle Scholar
- Pan XB, Qu XW, Jiang D, Zhao XL, Han JC, Wei L: BST2/Tetherin inhibits hepatitis C virus production in human hepatoma cells. Antiviral Res 2013, 98: 54-60. 10.1016/j.antiviral.2013.01.009PubMedView ArticleGoogle Scholar
- Weissenhorn W, Miguet N, Aschman N, Renesto P, Usami Y, Gottlinger HG: Structural basis of tetherin function. Curr HIV Res 2012, 10: 298-306. 10.2174/157016212800792487PubMedView ArticleGoogle Scholar
- Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J: Stimulation of NF-kappaB activity by the HIV restriction factor BST2. J Virol 2013, 87: 2046-2057. 10.1128/JVI.02272-12PubMedPubMed CentralView ArticleGoogle Scholar
- Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ: Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe 2012, 12: 633-644. 10.1016/j.chom.2012.10.007PubMedPubMed CentralView ArticleGoogle Scholar
- Mangeat B, Cavagliotti L, Lehmann M, Gers-Huber G, Kaur I, Thomas Y, Kaiser L, Piguet V: Influenza virus partially counteracts restriction imposed by tetherin/BST-2. J Biol Chem 2012, 287: 22015-22029. 10.1074/jbc.M111.319996PubMedPubMed CentralView ArticleGoogle Scholar
- Yin X, Hu Z, Gu Q, Wu X, Zheng YH, Wei P, Wang X: Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein. J Virol 2014, 88: 1259-1270. 10.1128/JVI.03148-13PubMedPubMed CentralView ArticleGoogle Scholar
- Morrison JH, Guevara RB, Marcano AC, Saenz DT, Fadel HJ, Rogstad DK, Poeschla EM: Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation. J Virol 2014, 88: 3255-3272. 10.1128/JVI.03814-13PubMedPubMed CentralView ArticleGoogle Scholar
- Jones PH, Maric M, Madison MN, Maury W, Roller RJ, Okeoma CM: BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). Virology 2013, 438: 37-49. 10.1016/j.virol.2013.01.010PubMedPubMed CentralView ArticleGoogle Scholar
- Blondeau C, Pelchen-Matthews A, Mlcochova P, Marsh M, Milne RS, Towers GJ: Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M. J Virol 2013, 87: 13124-13133. 10.1128/JVI.02250-13PubMedPubMed CentralView ArticleGoogle Scholar
- Celestino M, Calistri A, Del Vecchio C, Salata C, Chiuppesi F, Pistello M, Borsetti A, Palu G, Parolin C: Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein. J Virol 2012, 86: 6688-6700. 10.1128/JVI.07037-11PubMedPubMed CentralView ArticleGoogle Scholar
- Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T: Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009, 6: 54-67. 10.1016/j.chom.2009.05.008PubMedPubMed CentralView ArticleGoogle Scholar
- Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P: Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 2009, 106: 2886-2891. 10.1073/pnas.0811014106PubMedPubMed CentralView ArticleGoogle Scholar
- Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT: Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009, 5: e1000429. 10.1371/journal.ppat.1000429PubMedPubMed CentralView ArticleGoogle Scholar
- Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ: Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci USA 2009, 106: 20889-20894. 10.1073/pnas.0907075106PubMedPubMed CentralView ArticleGoogle Scholar
- Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451: 425-430. 10.1038/nature06553PubMedView ArticleGoogle Scholar
- Zenner HL, Mauricio R, Banting G, Crump CM: Herpes simplex virus 1 counteracts tetherin restriction via its virion host shutoff activity. J Virol 2013, 87: 13115-13123. 10.1128/JVI.02167-13PubMedPubMed CentralView ArticleGoogle Scholar
- Cook RF, Leroux C, Issel CJ: Equine infectious anemia and equine infectious anemia virus in 2013: a review. Vet Microbiol 2013, 167: 181-204. 10.1016/j.vetmic.2013.09.031PubMedView ArticleGoogle Scholar
- Dong JB, Zhu W, Cook FR, Goto Y, Horii Y, Haga T: Identification of a novel equine infectious anemia virus field strain isolated from feral horses in southern Japan. J Gen Virol 2013, 94: 360-365. 10.1099/vir.0.047498-0PubMedView ArticleGoogle Scholar
- Cook SJ, Cook RF, Montelaro RC, Issel CJ: Differential responses of Equus caballus and Equus asinus to infection with two pathogenic strains of equine infectious anemia virus. Vet Microbiol 2001, 79: 93-109. 10.1016/S0378-1135(00)00348-5PubMedView ArticleGoogle Scholar
- Dietrich I, McMonagle EL, Petit SJ, Vijayakrishnan S, Logan N, Chan CN, Towers GJ, Hosie MJ, Willett BJ: Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J Virol 2011, 85: 5840-5852. 10.1128/JVI.00071-11PubMedPubMed CentralView ArticleGoogle Scholar
- Takeda E, Nakagawa S, Nakaya Y, Tanaka A, Miyazawa T, Yasuda J: Identification and functional analysis of three isoforms of bovine BST-2. PLoS One 2012, 7: e41483. 10.1371/journal.pone.0041483PubMedPubMed CentralView ArticleGoogle Scholar
- Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, Desale H, Clemons B, Cahalan SM, Schuerer SC, Sanna MG, Han GW, Kuhn P, Rosen H, Stevens RC: Crystal structure of a lipid G protein-coupled receptor. Science 2012, 335: 851-855. 10.1126/science.1215904PubMedPubMed CentralView ArticleGoogle Scholar
- Lippold S, Knapp M, Kuznetsova T, Leonard JA, Benecke N, Ludwig A, Rasmussen M, Cooper A, Weinstock J, Willerslev E, Shapiro B, Hofreiter M: Discovery of lost diversity of paternal horse lineages using ancient DNA. Nat Commun 2011, 2: 450.PubMedView ArticleGoogle Scholar
- Andrew AJ, Miyagi E, Kao S, Strebel K: The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009, 6: 80. 10.1186/1742-4690-6-80PubMedPubMed CentralView ArticleGoogle Scholar
- Fukuma A, Abe M, Morikawa Y, Miyazawa T, Yasuda J: Cloning and characterization of the antiviral activity of feline Tetherin/BST-2. PLoS One 2011, 6: e18247. 10.1371/journal.pone.0018247PubMedPubMed CentralView ArticleGoogle Scholar
- Coleman CM, Spearman P, Wu L: Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology 2011, 8: 26. 10.1186/1742-4690-8-26PubMedPubMed CentralView ArticleGoogle Scholar
- Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD: Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139: 499-511. 10.1016/j.cell.2009.08.039PubMedPubMed CentralView ArticleGoogle Scholar
- Zhang J, Liang C: BST-2 diminishes HIV-1 infectivity. J Virol 2010, 84: 12336-12343. 10.1128/JVI.01228-10PubMedPubMed CentralView ArticleGoogle Scholar
- Cocka LJ, Bates P: Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog 2012, 8: e1002931. 10.1371/journal.ppat.1002931PubMedPubMed CentralView ArticleGoogle Scholar
- Weinelt J, Neil SJ: Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses. J Virol 2014, 88: 5845-5858. 10.1128/JVI.03818-13PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.